跳至主要内容
临床试验/NCT05314387
NCT05314387尚未招募不适用

A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty With SMR TT Hybrid Glenoid With or Without SMR Cementless Finned Short Stem

Limacorporate S.p.a0 个研究点目标入组 100 人开始时间: 2022年4月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
100
主要终点
Proportion of patients reaching a clinical progression from baseline to 24-month follow-up

研究概览

简要总结

Post-market, prospective, non randomized, open label, multicentre, clinical study analysing outcomes of shoulder arthroplasty with SMR TT Hybrid Glenoid with or without SMR Cementless Finned Short Stem

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Both genders;
  • Age ≥ 18 years old;
  • Full skeletal maturity;
  • Life expectancy over 5 years;
  • Patient is requiring primary unilateral arthroplasty based on physical examination and medical history;
  • Good bone quality evaluated by the Investigator and the intraoperative evaluation;
  • A diagnosis in the target shoulder of one or more of the S-11 SMR TT Hybrid Glenoid and Cementless Finned Short Stem Version Sep 2021 2.0 Confidential Page11 following:
  • Primary osteoarthritis;
  • Secondary osteoarthritis;
  • Post-traumatic arthritis;
  • Rheumatoid arthritis;
  • Avascular necrosis
  • acute fractures of the humeral head that cannot be treated with other fracture fixation methods;
  • cuff tear arthropathy (only in combination with CTA Heads);
  • Glenoid arthrosis without excessive glenoid bone loss: A1, A2 and B1 according to Walch classification.
  • Exclusion Criteria (Key):
  • Patient requiring revision shoulder arthroplasty;
  • Osteoporosis with a history of non-traumatic fractures;
  • Steroid injections within the previous 3 months;
  • Contralateral shoulder replacement within the previous 3 months;
  • Significant proven or suspicious infection of the target shoulder or any serious infectious disease before the study according to the Investigator;
  • Significant neurological or musculoskeletal disorders that may compromise functional recovery;
  • Not recovered axillary nerve palsy;
  • Non functioning deltoid muscle;
  • Known or suspicious hypersensitivity to the metal or other components and materials of the implant;
  • Participation in any experimental drug/device study within the 6 months prior to the preoperative visit;
  • Women of childbearing potential who are pregnant, nursing, or planning to become pregnant.
  • These are key eligibility criteria, other eligibility criteria apply.

排除标准

  • 未提供

结局指标

主要结局

Proportion of patients reaching a clinical progression from baseline to 24-month follow-up

时间窗: 24 Months

The primary endpoint consists of the proportion of patients reaching a clinical progression from baseline to 24-month follow-up measured as: * Constant score improvement of greater than 10; * Adjusted Constant score greater than or equal to 54.

次要结局

  • Measure American Shoulder and Elbow Surgeons Shoulder Score (ASES)(Baseline to 24 and 60 Months)
  • Measure Oxford shoulder score(Baseline to 24 and 60 Months)
  • Measure Constant Score(Baseline to 24 and 60 Months)
  • Measure Simple Shoulder Test(Baseline to 24 and 60 Months)
  • Stability of the SMR TT hybrid glenoid component with or without SMR cementless finned short stem(Immediately postoperative to 24 Months)
  • System conversion rate, intended as a conversion within the SMR system from anatomic to reverse(24 Months)
  • Measure Patient Satisfaction(Baseline to 24 and 60 Months)
  • Failure rate, intended as removal of the SMR TT hybrid glenoid component(Immediately postoperative to 24 Months)
  • Failure rate, intended as removal of the SMR cementless finned short stem(Immediately postoperative to 24 Months)
  • Survival rate (Kaplan-Meier)(60 Months)
  • Incidence of device-related AE/SAE (ADE/SADE)(Immediately postoperative to 24 and 60 Months)

研究者

发起方
Limacorporate S.p.a
申办方类型
Industry
责任方
Sponsor

相似试验

S-11 SMR TT Hybrid Glenoid and Cementless Finned... | 临床试验